Search


EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market,...
Jun 14


ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
The data showed a 62% CR/sCR at a median follow-up of 9.5 months. He discusses the patient population, next steps, and the work that...
Dec 8, 2024


Arcellx's CEO on Friday's #ASH23 topline release and his take on the BCMA field
Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti and gives his take on the recent FDA notice about CAR-T.
Dec 9, 2023


Arcellx’s CMO gives an update on their BCMA program at the 2023 CAR-TCR Summit
Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.
Aug 30, 2023


Talking BCMA CAR-T at #JPM23
Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.
Jan 11, 2023